Results of a Dose-Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non–Small Cell Lung Cancer

Enriqueta Felip*, Mauricio Burotto, Zanete Zvirbule, Luis A. Herraez-Baranda, Pascal Chanu, Smita Kshirsagar, Vidya Maiya, Phyllis Chan, Emanuela Pozzi, Mathilde Marchand, Marion Monchalin, Kunihiko Tanaka, Nadia Tosti, Bei Wang, Eleonora Restuccia

*Autor correspondiente de este trabajo

Producción científica: Contribución a una revistaArtículorevisión exhaustiva

10 Citas (Scopus)


Intravenous (IV) atezolizumab is approved for non–small cell lung and other cancers. Subcutaneous (SC) atezolizumab coformulated with recombinant human hyaluronidase, a permeation enhancer for SC dispersion and absorption, is being developed to improve treatment options, reduce burden, and increase efficiency for patients and practitioners. IMscin001 (NCT03735121), a 2-part, open-label, global, multicenter, phase 1b/3 study, is evaluating the pharmacokinetics (PK), safety, and efficacy of SC atezolizumab. The part 1 (phase 1b) objective was determination of an SC atezolizumab dose yielding a serum trough concentration (Ctrough) comparable with IV. Patients enrolled in 3 cohorts received SC atezolizumab 1800 mg (thigh) once (cohort 1), 1200 mg (thigh) every 2 weeks for 3 cycles (cohort 2), or 1800 mg (abdomen) every 3 weeks cycle 1, then cycles 2 and 3 (thigh) every 3 weeks (cohort 3). In subsequent cycles, IV atezolizumab 1200 mg every 3 weeks was administered until loss of clinical benefit. SC atezolizumab 1800 mg every 3 weeks and 1200 mg every 2 weeks provided similar Ctrough and area under the curve values in cycle 1 to the corresponding IV atezolizumab reference, was well tolerated, and exhibited a safety profile consistent with the established IV formulation. Exposure following SC injection in the abdomen was lower (20%, 28%, and 27% for Ctrough, maximum concentration, and area under the concentration-time curve from time 0 to day 21, respectively) than in the thigh. Part 1 SC and IV PK data were analyzed using a population PK modeling approach, followed by simulations. Part 2 (phase 3) will now be initiated to demonstrate that SC atezolizumab PK exposure is not lower than that of IV.

Idioma originalInglés
Páginas (desde-hasta)1142-1155
Número de páginas14
PublicaciónClinical Pharmacology in Drug Development
EstadoPublicada - oct. 2021
Publicado de forma externa

Nota bibliográfica

Funding Information:
L.A.H.‐B. and E.R. are employees of and hold stock in F. Hoffmann‐La Roche. P.C. is an employee of Genentech/Roche and holds stock in Roche Holding Ltd. S.K. is an employee of ProUnlimited. V.M., P.C., and B.W. are employees of Genentech, Inc. E.P., M.M., and N.T. are employees of F. Hoffmann‐La Roche Ltd. M.M. is an employee of Certara and has received consulting fees from Genentech, Inc., in connection with this work. K.T. is an employee of Chugai Pharmaceutical Co., Ltd., and has received financial support from Genentech, Inc. All authors received support for third‐party writing assistance for this manuscript, provided by F. Hoffmann‐La Roche Ltd.

Funding Information:
IMscin001 (NCT03735121) is a 2‐part, open‐label, global, multicenter, phase 1b/3 study to evaluate the PK, safety, and efficacy of SC atezolizumab compared with IV atezolizumab in patients with locally advanced or metastatic NSCLC. This clinical study was sponsored by F. Hoffmann‐La Roche Ltd (Basel, Switzerland). It was conducted in full concordance with the International Council for Harmonisation E6 guideline for Good Clinical Practice and the principles of the Declaration of Helsinki.

Publisher Copyright:
© 2021 The Authors. Clinical Pharmacology in Drug Development published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology


Profundice en los temas de investigación de 'Results of a Dose-Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non–Small Cell Lung Cancer'. En conjunto forman una huella única.

Citar esto